This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients

Pfizer Inc. (NYSE: PFE) announced today the results of studies on Lyrica ® (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu. The studies included exploratory research designed to provide new insight into how Lyrica works in the brains of patients with fibromyalgia. A total of seven Lyrica abstracts were presented.

Pfizer and study investigators presented three abstracts from the first study to use functional magnetic resonance imaging (fMRI) to measure the effects of Lyrica on brain activity in fibromyalgia patients. In this exploratory study, Lyrica decreased connectivity between various parts of the brain involved in pain processing, an important effect considering that fibromyalgia patients have elevated intrinsic connectivity. Additionally, the fMRI study suggested Lyrica reduced visual activation or sensory stimulation that activates pain and affects related brain regions in fibromyalgia patients. In an additional fMRI analysis, Lyrica was found to affect grey matter density in parts of the brain known to process pain. In this study, the most common adverse event in Lyrica-treated patients was dizziness when compared with placebo. The adverse event profile is consistent with that known for Lyrica.

It has been hypothesized that the central nervous system (CNS) in patients with fibromyalgia is hyper-sensitive to pain signals. These are the first exploratory data using fMRI and Lyrica that suggests an association between treatment and changes in central pain processing pathways in FM patients.

“This is the first exploratory fMRI study to investigate the mechanism of action of Lyrica in humans with fibromyalgia,” said study investigator Richard E. Harris, Ph.D., Assistant Professor, Department of Anesthesiology and Research Assistant Professor, Department of Internal Medicine, University of Michigan. “This exploratory study not only shows how fibromyalgia affects the brain, it provides further insights on how Lyrica may impact central pain processing pathways in the brain.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs